Literature DB >> 13662215

The comparative effects of phenylbutazone and G27202 (metabolite I) in patients with rheumatoid arthritis: an assessment of methods for antirheumatic drug evaluation.

P P VAUGHN, D S HOWELL, I M KIEM.   

Abstract

Entities:  

Keywords:  ARTHRITIS, RHEUMATOID/therapy; PHENYLBUTAZONE/related compounds

Mesh:

Substances:

Year:  1959        PMID: 13662215     DOI: 10.1002/1529-0131(195906)2:3<212::aid-art1780020304>3.0.co;2-q

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  7 in total

1.  A controlled trial of phenylbutazone, oxyphenbutazone, and a placebo in the treatment of rheumatoid arthritis.

Authors:  R I MEANOCK; E LEWIS-FANING
Journal:  Ann Rheum Dis       Date:  1961-06       Impact factor: 19.103

2.  Clinical trial of the therapeutic value of certain antirheumatic drugs.

Authors:  S A den OUDSTEN
Journal:  Ann Rheum Dis       Date:  1960-09       Impact factor: 19.103

3.  Controlled trial of G27 202 (p-hydroxyphenyl-butazone) in rheumatoid arthritis.

Authors:  N CARDOE
Journal:  Ann Rheum Dis       Date:  1959-09       Impact factor: 19.103

4.  Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.

Authors:  P L Boardman; F D Hart
Journal:  Br Med J       Date:  1967-11-04

5.  A preliminary report of the anti-inflammatory effect of oxyphenbutazone (G27202) in postoperative obstetrical and gynecological practice.

Authors:  W D FRASER; P J BEARDALL; G B MAUGHAN
Journal:  Can Med Assoc J       Date:  1961-08-05       Impact factor: 8.262

6.  Effects of oxyphenbutazone (tandearil) on plasma seromucoids. II. In postoperative inflammation.

Authors:  R BARCELO; C LEBLANC; P RIOPEL; L P LEGRESLEY
Journal:  Can Med Assoc J       Date:  1963-03-23       Impact factor: 8.262

7.  Effects of oxyphenbutazone (Tandearil) on plasma seromucoids. I. In experimental inflammation.

Authors:  R BARCELO; P RIOPEL; L P LEGRESLEY
Journal:  Can Med Assoc J       Date:  1963-03-16       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.